Plain-English translation of NCT06224530 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers want to understand whether , a medication typically used for seizures, might help people showing early warning signs of psychosis. The study will measure how this medication affects brain activity, brain chemistry, and thinking abilities in young adults (ages 18–40) who are at risk for psychosis but haven't experienced a full psychotic episode yet. This is an exploratory study to see if the medication could be helpful for people in this early stage.
Some research suggests that certain brain areas may be overactive in people at risk for psychosis, and that brain chemistry imbalances may play a role in these early symptoms. This study is investigating whether this medication could help regulate brain activity and reduce the likelihood of developing psychosis.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a screening visit (about 2 hours) where researchers will ask about your health and do some basic tests. Then you will return for two scanning visits, about a week or two apart. At each scanning visit, you will take either the medication or a placebo (a dummy pill), and then have an MRI brain scan while researchers measure your brain activity. You will also complete some thinking and memory tests. The whole study takes a few weeks from start to finish.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United Kingdom